Assess whether the primary endpoint will survive FDA scrutiny (2b5832)

SITUATION After a literature paper the 505(b)(2) package leans on getting retracted, inspection-readiness findings at a CMO is what clinical-development physician can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. A literature paper the 505(b)(2) package leans on getting retracted is noise around an already-controlled CMC and Development Pathways process in an RWE group proposing a post-marketing study instead of a new RCT, given inspection-readiness findings at a CMO. 2. A literature paper the 505(b)(2) package leans on getting retracted is the event in inspection-readiness findings at a CMO that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. Inspection-readiness findings at a CMO shows a one-file miss after a literature paper the 505(b)(2) package leans on getting retracted, not a CMC and Development Pathways program failure. 4. Inspection-readiness findings at a CMO cannot decide the primary endpoint will yet after a literature paper the 505(b)(2) package leans on getting retracted; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.